Johnson & Johnson (J&J) plans to acquire Alios BioPharma, a private company specializing in treatments for viral diseases, for $1.75 billion, the companies have announced.
The all-cash deal will include an Alios medication still under trial for treating infants with respiratory syncytial virus, a common ailment in young children.
"Alios BioPharma's pipeline is closely aligned with our vision to continue to address important unmet medical needs through scientific innovation," said Johan Van Hoof, the global head of infectious diseases at J&J.
The companies said the transaction is likely to close in the fourth quarter following standard antitrust reviews.
